category,datetime,headline,id,image,related,source,summary,url
company,1768258805,Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing,138081043,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,GILD,Yahoo,"In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.",https://finnhub.io/api/news?id=a387c003c518fe09b45adf99b5ad19ffe3a9e90dd71cc97be2d3ee700c6de772
company,1768239621,Gilead Sciences: From All-Time Highs To Higher Highs,138078945,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1958960897/image_1958960897.jpg?io=getty-c-w1536,GILD,SeekingAlpha,"Gileadâs Yeztugo launch, rising margins, and CAR-T pipeline progress (anito-cel, KITE-753/363) support a 2026 bull caseâread the outlook now.",https://finnhub.io/api/news?id=98acfd77875786e8d559978005ee16a3b1a789ed2a121272d2d0fcf0342e906a
company,1768235700,Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains,138126230,,GILD,MarketWatch,Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains,https://finnhub.io/api/news?id=c84e2272b271d710b7c691f6bb03a5560585750da26344ca38dc3687cfd7d440
company,1768232763,"Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",138078583,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,GILD,SeekingAlpha,"Gilead Sciences, Inc. (GILD) 44th Annual J.P.",https://finnhub.io/api/news?id=3482d457ee4e65d8413d3fc654fc867daee00c710ca213f1dd6c62fa28a9e9bd
company,1768210272,UBS and Citi Go Bullish on Gilead Sciences (GILD),138071500,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,GILD,Yahoo,"Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from […]",https://finnhub.io/api/news?id=3afbb2fe454ee95c36d9d540589831cc2221552830486a3bf307096fe433c122
company,1768208676,Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history,138075988,https://image.cnbcfm.com/api/v1/image/108251114-17682257611768225758-43458680393-1080pnbcnews.jpg?v=1768225760&w=1920&h=1080,GILD,CNBC,"Daniel O’Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication, drug pipeline outlook, impact of AI, and more.",https://finnhub.io/api/news?id=87e539dde7646d7820229d28c082c2a8131e770fff8d6d7c24cd6dfc173f8019
company,1768191848,The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration,138069115,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,GILD,Yahoo,"On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead’s continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we’ll examine how this...",https://finnhub.io/api/news?id=3dcc842b152e5723484bf861e2526dbd746702b6159fd82b1c2a4ff693187676
